Item 8.01 Other Events.

On June 4, 2021, Surface Oncology, Inc. (the "Company") announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. Preliminary SRF388 results indicate promising single-agent activity in a heavily pre-treated population, including a confirmed partial response demonstrating 66% tumor shrinkage and symptomatic improvement in a patient with squamous cell non-small-cell lung carcinoma ("NSCLC"), whose disease was resistant to three prior regimens including chemotherapy and PD-1 blockade. In addition, early data from SRF617's combination cohorts point to its potential as a combination therapy, including an unconfirmed partial response with an approximate 50% tumor shrinkage in a patient with pancreatic cancer receiving second-line treatment with SRF617 in combination with gemcitabine/albumin-bound paclitaxel (Abraxane®). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Also on June 4, 2021, the Company will hold a webcast to review data from its ongoing SRF388 and SRF617 Phase 1 clinical studies. The slide presentation to be presented during the webcast is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



  Exhibit
  Number    Description

  99.1        Press release issued by Surface Oncology, Inc. on June 4, 2021

  99.2        Presentation of Surface Oncology, Inc. dated June 4, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses